Biaryl amide compounds as kinase inhibitors
The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
1. A compound, or a pharmaceutically acceptable salt thereof, selected from:
2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.
3. A combination comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.
4. The compound according to claim 1 that is:
or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1 that is:
or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 1 that is:
or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1 that is:
or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1 that is:
or a pharmaceutically acceptable salt thereof.